Introduction
============

Non-coding RNAs (ncRNAs) are regarded as regulators of cell cycle progression, proliferation, and fate. There are numerous classes of ncRNAs, including very long ncRNAs, PIWI-associated ncRNAs, and small interfering RNAs. However few have been described with respect to hematopoiesis. Here we review the current understanding of the role of microRNAs (miRNA) and long non-coding RNAs (lncRNAs) in the pathogenesis of acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).

Regulatory microRNAs in Leukemia
================================

MicroRNAs, negative regulators of gene expression, are initially transcribed as long primary miRNAs by RNA polymerase II, and subsequently processed by the nuclear ribonuclease Drosha and the cytoplasmic dsRNA-specific endonuclease Dicer. Mature miRNAs, averaging 22 nucleotides, associate with the RNA induced silencing complex (RISC) that aids in generating their repressive functions. The most efficient miRNA targeting is achieved by mature miRNAs binding to the 3′-untranslated regions (UTR) of target messenger RNAs (mRNA) leading to translational inhibition or mRNA cleavage (Zhang et al., [@B70]). miRNAs also bind within coding regions and 5′UTRs, through which additional regulation of mRNA translation can be mediated (Figure [1](#F1){ref-type="fig"}; Ørom et al., [@B60]; Tay et al., [@B65]). miRNAs have garnered much interest due to their role as post-transcriptional regulators of genes involved in numerous physiologic and developmental processes including cellular proliferation, cell cycle progression, and apoptosis (reviewed in Lee and Ambros, [@B46]; Cheng et al., [@B17]; Hayashita et al., [@B31]; Ivanovska et al., [@B36]). Altered miRNA expression has been implicated in the pathology of leukemia, where some miRNAs are proposed to function either as tumor suppressor genes (TS) or oncogenes (Table [1](#T1){ref-type="table"}; Esquela-Kerscher and Slack, [@B21]).

###### 

**Characteristics of discussed ncRNAs[^a^](#tfn1){ref-type="table-fn"}**.

  ncRNA(s)                                                                                                               ncRNA class   Target                                Disease association       Clinical relevance                                                               Citation
  ---------------------------------------------------------------------------------------------------------------------- ------------- ------------------------------------- ------------------------- -------------------------------------------------------------------------------- ---------------------------------------------------
  miR-29b                                                                                                                miRNA         DNMT3a and DNMT3b, DNMT1 (indirect)   AML                       Predictive response to therapy; potentially therapeutic                          Garzon et al. ([@B26])
  miR-126/126\*                                                                                                          miRNA         N/A                                   AML                       Diagnostic: CBF                                                                  Li et al. ([@B49])
  miR-224, -368, -382                                                                                                    miRNA         N/A                                   AML                       Diagnostic: *t*(15; 17)                                                          Li et al. ([@B49])
  miR-126, -126\*, -224, -368, -382, -17-5p, -20a                                                                        miRNA         N/A                                   AML                       Diagnostic: MLL-rearrangement                                                    Li et al. ([@B49])
  miR-21                                                                                                                 miRNA         PTEN                                  AML                       Diagnostic: *t*(6; 11) vs. *t*(9; 11), prognostic                                Garzon et al. ([@B23])
  miR-29b                                                                                                                miRNA         TCL1                                  AML                       Diagnostic: balanced 11q23 translocations; potentially therapeutic               Garzon et al. ([@B23])
  miR-155                                                                                                                miRNA         Unknown in AML                        AML                       Diagnostic: FLT3--ITD mutations                                                  Garzon et al. ([@B23])
  miR-199a, -191                                                                                                         miRNA         N/A                                   AML                       Prognostic                                                                       Garzon et al. ([@B23])
  miR-181                                                                                                                miRNA         TLR and IL1-β                         AML                       Prognostic                                                                       Marcucci et al. ([@B52])
  (miR-128a, -128b) vs. (miR-223, let-7b\]                                                                               miRNA         N/A                                   AML vs. ALL               Diagnostic                                                                       Mi et al. ([@B55])
  miR-18a, -532, -218, -625, 193a, -638, -550, -663                                                                      miRNA         N/A                                   ALL                       Prognostic                                                                       Zhang et al. ([@B71])
  miR-143                                                                                                                miRNA         MLL--AF4                              ALL                       Prognostic, potentially therapeutic                                              Dou et al. ([@B19])
  miR-15a, -16-1                                                                                                         miRNA         Bcl2                                  CLL                       Potentially therapeutic                                                          Bandi et al. ([@B4])
  miR-29, -181                                                                                                           miRNA         TCL1                                  CLL                       Prognostic, potentially therapeutic                                              Pekarsky et al. ([@B62])
  miR-15a, -195, -221, -23b, -155, -223, -29a, -24, -29b, -146, -16, -16-2, -29c                                         miRNA         N/A                                   CLL                       Diagnostic: expressed ZAP-70 and unmutated IgVH vs. no ZAP-70 and mutated IgVH   San Jose-Eneriz et al. ([@B63])
  miR-7, -23a, -26a, -29a, -29c, -30b, -30c, -100, -126, -134, -141, -183, -196b, -199a, -224, -362, -422b, 520a, -191   miRNA         N/A                                   CML                       Predictive response to therapy                                                   San Jose-Eneriz et al. ([@B63])
  ANRIL, p15AS                                                                                                           Antisense     p15                                   AML/ALL                   Diagnostic, potentially prognostic                                               Yu et al. ([@B69]); Iacobucci et al. ([@B35])
  lincRNA-p21                                                                                                            lincRNA       BCR-ABL                               Potentially CML           Potentially therapeutic                                                          Notari et al. ([@B58]); Du et al. ([@B20])
  MEG3                                                                                                                   lincRNA       p53, GDF15                            MDS/AML                   Prognostic                                                                       Benetatos et al. ([@B6])
  Combined T-UCR and miR profile                                                                                         UCR           N/A                                   CLL/AML                   Diagnostic: tumor type; prognostic                                               Calin et al. ([@B13])
  Dleu2                                                                                                                  lincRNA       miR-15a/16                            CLL                       Diagnostic, potentially therapeutic                                              Migliazza et al. ([@B56]); Lerner et al. ([@B47])
  HOTAIRM1                                                                                                               Antisense     HOXA1, HOXA4, CD11b, CD18             Hematopoietic regulator   Potentially therapeutic                                                          Zhang et al. ([@B72])
  EGO                                                                                                                    Antisense     MBP, EDN                              Hematopoietic regulator   Potentially therapeutic                                                          Wagner et al. ([@B67])
  lincRNA-a7                                                                                                             lncRNA        SCL/TAL1                              Hematopoietic regulator   Potentially therapeutic                                                          Ørom et al. ([@B59])

*^a^ Non-coding RNAs having different diagnostic or therapeutic roles in different leukemia subtypes are listed separately*.

![**(A)** Regulatory microRNA mechanisms in leukemia. **(A1)** Perfect base complementarity between miRNA and target mRNA can lead to target mRNA degradation. **(A2)** Imperfect base complementarity between miRNA and target mRNA can lead to mRNA translational repression. **(B)** Currently hypothesized mechanisms of lncRNA regulation in leukemia. **(B1)** Recruitment of PcGs leads to stable repression, although the mechanism of lncRNA association with the target sequence is unknown. **(B2)** lncRNAs can influence miRNA cluster transcriptional activity, and can be post-transcriptionally regulated by miRNAs. **(B3)** Activator lncRNAs enhance transcriptional or binding affinity of transcription factors, although the mechanism of lncRNA association with the target sequence is unknown.](fgene-02-00094-g001){#F1}

miRNAs in AML
=============

Acute myeloid leukemia is characterized by the abnormal proliferation and accumulation of immature myeloblasts in the bone marrow and blood. Diagnosis is based on the presence of malignant blasts in the bone marrow as well as distinctive translocations and gene mutations. AML represents a group of heterogeneous disorders with striking differences in survival based on cytogenetics, prognostic gene mutations, and age and has an average long-term overall survival (OS) rate of approximately 25--60% depending on the above characteristics in patients over age 55 (Heerema-McKenney and Arber, [@B32]; <http://seer.cancer.gov>, accessed September 24, 2011).

Golub et al. ([@B28]) first demonstrated that expression profiling of protein-encoding genes could distinguish AML from ALL, pioneering the way for expression-based diagnostic approaches. The advent of miRNA expression profiling further distinguished AML from ALL and has been used to explore possible associations of miRNAs with regard to diagnosis, prognosis, and response to treatment (Calin and Croce, [@B10]; Mi et al., [@B55]). Garzon et al. ([@B24]) reported that the expression of *miR-29* family member miR-29b is often down-regulated in primary AML with respect to bone marrow CD34+ progenitors. miR-29b directly targets the 3′UTR of DNA methyltransferases *DNMT3a* and *DNMT3b* and indirectly targets *DNMT1* via negative regulation of *SP1*, a transactivator of *DNMT1*. Down-regulation of the methyltransferases caused by forced expression of miR-29b leads to altered DNA methylation and subsequent repression of TS genes such as *p15^INK4b^* and *ESR1* often observed in myeloid leukemogenesis (Garzon et al., [@B26]). Restoration of miR-29b increases sensitivity to the hypomethylating agent, decitabine, in patients with AML over age 60 (Blum et al., [@B7]). Forced expression of miR-29b in AML cell lines and primary AML samples reduces cell growth and induces apoptosis, indicative of its TS activity in acute leukemia. Additional support was provided by the dramatic reduction of tumors in a xenograft leukemia model in response to miR-29b over-expression. Following miR-29b expression, gene expression analysis of the AML cell line K562 showed that miR-29b, along with miR-29a, target pathways involved with cell cycle, proliferation, and apoptosis (Garzon et al., [@B25]). Together these data suggest that synthetic *miR-29b* oligonucleotides could potentially serve as a therapeutic approach in AML.

Just as numerous groups have identified mRNA signatures distinguishing AML subclasses, several groups have associated miRNA signatures with cytogenetic abnormalities and predictors of outcome in AML (Bullinger et al., [@B9]; Valk et al., [@B66]). Li et al. reported that miRNA expression signatures accurately discriminate between AMLs with the common translocations *t*(15; 17), *t*(8; 21), and inv(16), all of which represent favorable prognosis rearrangements that result in the disruption of core-binding factors (CBF). Expression of two (miR-126/126\*), three (miR-224, -368, and -382), and seven (miR-126, -126\*, -224, -368, -382, -17-5p, and -20a) miRNAs distinguishes CBF *t*(8; 21) and inv16, *t*(15; 17) and MLL-rearrangement AMLs, respectively, from one another (Li et al., [@B49]). Up-regulation of miR-21 distinguishes AMLs with *t*(6; 11) from those with *t*(9; 11), while down-modulation of miR-29 correlates with balanced 11q23 translocations. miR-155 shows increased expression in patients with AML characterized by FLT3--ITD mutations (Garzon et al., [@B23]).

Expression patterns of miRNAs are also associated with prognosis. Marcucci et al. ([@B52]) have associated a worse prognosis in patients with *t*(6; 11) who display increased expression of miR-21, an inhibitor of the TS PTEN. This group has also shown that patients with AML that express elevated miR-199a and -191 have a significantly lower OS and event-free survival (Garzon et al., [@B23]). The miR-181 family has been shown to contribute to an aggressive AML phenotype through mechanisms associated with the activation of pathways controlled by toll-like receptors and interleukin-1β (Marcucci et al., [@B52]).

miRNAs in ALL
=============

Acute lymphoblastic leukemia represents a heterogeneous group of disorders that result in the malignant transformation of lymphoblasts at various stages of differentiation. Although more common in children, ALL also occurs in adults, with a shift from childhood-prevalent to adulthood-prevalent subtypes during adolescence. A diagnosis of ALL occurs when blood and bone marrow samples show a large number of abnormal lymphocyte blasts. Treatment options are based on ALL subtype and prognostic factors such as age.

Mi et al. ([@B55]) have shown that expression signatures of as few as two miRNAs can discriminate ALL from AML; miR-128a and -128b were significantly higher in ALL, whereas miR-223 and let-7b were expressed at significantly higher levels in AML. This study also demonstrated that lineage discriminating miRNAs could differentiate ALL samples from AML samples even when both leukemias displayed the same translocation/fusion events such as *t*(11; 19)(q23; p13.3)/MLL--ENL (Mi et al., [@B55]). Zhang et al. identified an 8-miRNA-expression profile (miR-18a, -532, -218, -625, -193a, -638, -550, and -663) that differentiates good from poor steroid response in pediatric ALL. miRNA expression signatures were also able to identify relapse and non-relapse pediatric cases (Zhang et al., [@B71]). miR-143 has been shown to negatively regulate the MLL--AF4 fusion protein, a product of the translocation *t*(4; 11)(q21; q23), which confers poorer prognosis compared to other MLL arrangements. Restoration of miR-143 in MLL--AF4-positive cells induced apoptosis by reducing MLL--AF4 fusion protein levels, suggesting that forced expression of miR-128 could serve as a therapeutic agent in MLL--AF4 ALL (Dou et al., [@B19]).

miRNAs in CLL
=============

Chronic lymphocytic leukemia, the most common leukemia found in adults, results from immature, malignant resting B cell lymphocytes overexpressing the anti-apoptotic B cell lymphoma 2 (Bcl2) protein and accumulating in the bone marrow and the blood (Cimmino et al., [@B18]). Of those diagnosed with CLL, most are over the age of 50. CLL exhibits clinical heterogeneity as marked by the observation that some patients present with aggressive leukemia requiring immediate treatment while others require no intervention for many years (Li et al., [@B48]).

The first demonstration of miRNA association with pathogenesis was discovered in CLL (Calin et al., [@B11]). The Croce group showed that miR-15a and -16 reside in the fragile chromosomal band 13q14, which is deleted in more than half of CLL cases, as well as some prostate tumor and retinoblastoma samples (Chen et al., [@B16]; Kivelä et al., [@B43]). They went on to show that miR-15a and -16 negatively regulate cell growth and cell cycle progression (Calin et al., [@B11]). Additionally, over-expression of these miRNAs has been shown to repress Bcl2 expression and induce apoptosis in a leukemic cell line model, indicating a potential therapeutic role for miR-15a and -16 in the treatment of Bcl2-overexpressing tumors (Bandi et al., [@B3]).

Two markers of aggressive CLL include up-regulated 70-kDa zeta-associated protein (ZAP-70) and unmutated immunoglobulin variable genes (IgVH). When these factors are expressed at high levels they are associated with high levels of TCL1, an oncogene that co-activates the anti-apoptotic oncoprotein AKT and aids in regulatory pathways involved in cell survival and death. miR-29 and -181 have been shown to negatively regulate TCL1. Clinical CLL samples show miR-29 and -181 expression is inversely related to TCL1 expression, suggesting that these miRNAs could potentially serve as prognostic markers of CLL progression and as therapeutic agents in aggressive forms of TCL1-overexpressing CLL (Pekarsky et al., [@B62]). Calin et al. ([@B12]) demonstrated that 13 miRNAs (miR-15a, -195, -221, -23b, -155, -223, -29a, -24, -29b, -146, -16, -16-2, and -29c) could discriminate between patients expressing ZAP-70 and unmutated IgVH and those not expressing ZAP-70 and mutated IgVH, thereby distinguishing aggressive from indolent CLL.

miRNAs in CML
=============

Chronic myeloid leukemia is a malignant clonal stem cell disorder characterized by an increase of mature granulocytes in the bone marrow and blood. It often expresses the constitutively active BCR-ABL tyrosine kinase formed by a translocation that links *Abl1* on chromosomal band 9q34 to a portion of *BCR* on chromosomal band 22q11. CML is often suspected on the basis an extremely elevated white blood cell count with maturation of white blood cells and few or no leukemic blasts. Treatment and prognosis depend primarily on the phase of CML, i.e., whether in chronic, accelerated, or blast crisis. The development of the BCR-ABL1 kinase inhibitor, imatinib mesylate, as well as other Bcr--Abl inhibitors, has significantly improved treatment and outcome of patients with CML (Kantarjian et al., [@B39]). Jose-Eneriz et al. ([@B37]) identified 19 miRNAs (18 up-regulated: miR-7, -23a, -26a, -29a, -29c, -30b, -30c, -100, -126, -134, -141, -183, -196b, -199a, -224, -362, -422b, -520a, and 1 down-regulated: miR-191) that are differentially expressed between imatinib resistant and responder samples.

Long Non-Coding RNAs in Leukemia
================================

Long non-coding RNAs are ncRNAs greater than 200 nucleotides long, transcribed by RNA polymerase II or III, and can account for nearly 60% of all non-ribosomal and non-mitochondrial RNA in human cells (Kapranov et al., [@B40]). LncRNAs are involved in transcriptional silencing, chromatin remodeling, and gene activation (reviewed in Huarte and Rinn, [@B34]; Gibb et al., [@B27]) and originate from many chromosomal environments, including antisense to protein-coding genes, intergenic DNA (termed "lincRNAs" for long intergenic non-coding RNAs'), and from ultraconserved regions (Carninci et al., [@B15]). Excluding the latter, only a few lncRNA primary sequences are evolutionarily conserved (Guttman et al., [@B30]; Baker, [@B2]). In contrast to miRNAs, several cases have shown that conservation of secondary structure is more important to preserving ncRNA function than nucleotide sequence (Yap et al., [@B68]). Although lncRNAs in leukemia are not as extensively characterized as they are in some other tumor types, recent progress has identified several high profile targets that could alter how lncRNAs are viewed in terms of leukemia development, classification, and therapeutic targeting.

Suppressors of Tumor Suppressors are Oncogenes
==============================================

The INK4A--ARF--INK4B locus is deregulated in up to 40% of human cancers (Sherr, [@B64]; Kim and Sharpless, [@B42]). In addition to p15^INK4b^, p14^ARF^, and p16^INK4a^, TS genes interact closely with p53 and Rb to regulate cell cycle progression (Bandi et al., [@B3]). Pasmant et al. identified a polyadenylated lncRNA that was transcribed antisense to p15^INK4b^. The full-length transcript, ANRIL (antisense ncRNAs in the INK4 locus) has several isoforms (Pasmant et al., [@B61]). The p15AS variant, isolated from two AML cell lines, was significantly up-regulated in 11 of 16 AML and ALL primary samples (Yu et al., [@B69]). The authors demonstrated that p15AS was responsible for Dicer-independent silencing of p15^INK4b^ by altering H3K9me2 and H3K4me2 levels at both endogenous and exogenous p15^INK4b^ promoters. EZH2 and SUZ12 were required for stable silencing of p15^INK4b^, even after p15AS repression, indicating the likely recruitment of the polycomb repressive complex 2 (PRC2). Other reports demonstrated ANRIL-CBX7 interacts with either di- or tri-methylated H3K27, implying that ANRIL-mediated silencing works through both PRC1 and PRC2 complexes (Figure [1](#F1){ref-type="fig"}; Group et al., [@B29]; Kotake et al., [@B45]; Margueron and Reinberg, [@B53]). A study by Iacobucci et al. ([@B35]) involving acute leukemia and normal peripheral blood cells showed a statistically significant association between an ANRIL nucleotide polymorphism and ALL phenotype, demonstrating the importance of regulated ANRIL expression in primary leukemia.

Acting downstream of ANRIL, lincRNA-p21 is a 3.1-kb transcript induced by p53 expression that represses cellular proliferation by both p53-dependent and independent mechanisms (Huarte et al., [@B33]). LincRNA-p21 contains two canonical p53 binding sites in a promoter distinct from its closest neighbor, CDNK1A. Independent knock-down of either p53 or lincRNA-p21 produces significantly overlapping gene set enrichments (*p* \< 10^−200^), implying at least a partial overlap of apoptosis-induction mechanisms. Interestingly, in p53^−/−^ cell lines, lincRNA-p21 cannot direct proper localization and function of the pre-mRNA binding protein hnRNP-K (Huarte et al., [@B33]). Although these functional studies were done in mouse embryonic fibroblasts and human lung carcinoma cell lines, two reports demonstrate that BCR-ABL stimulates hnRNP-K expression and stability, subsequently promoting tumor progression (Notari et al., [@B58]; Du et al., [@B20]). Although the activity of lincRNA-p21 in acute or chronic leukemia is currently unknown, these data suggest that further work in CML is warranted.

p53-Interacting Tumor Suppressor lncRNAs
========================================

A second p53-regulating lincRNA, MEG3, was highlighted in human malignancies when investigators reported high expression levels in normal gonadotrophs and severely reduced expression in tumor-derived gonadotroph cells (Zhang et al., [@B75]). Forcing re-expression of MEG3 in HCT-116 cells leads to p53 accumulation and inhibition of cellular proliferation, indicative of a high-level regulator of p53-dependent TS activities (Zhang et al., [@B75]; Zhou et al., [@B76]). Although MEG3 isoforms can contain several small open reading frames, they are not required for p53-mediated cellular activities (Zhou et al., [@B76]; Zhang et al., [@B73]). Instead, MEG3 secondary structure is critical to maintaining function, including down-regulation of MDM2 expression and enhanced p53 binding to a specific subset of gene promoters, including GDF15 (Figure [1](#F1){ref-type="fig"}; Zhang et al., [@B73]). Of interest, MEG3 can suppress cell growth in p53^null^ cells, indicating p53-independent activities as well (Zhou et al., [@B76]).

Expression of the MEG3-DLK1 locus is tightly regulated by two differentially methylated regions (DMRs), which are hypermethylated in a subset of solid tumors and suppress MEG3 expression (Kagami et al., [@B38]; Astuti et al., [@B1]). Benetatos et al. ([@B6]) examined a cohort of 85 patients with either myelodysplastic syndrome (MDS) or AML. They found that 48% (20/42) of patients with AML displayed aberrant hypermethylation of the MEG3 promoter, which significantly correlated with decreased OS (HR 1.98, *p* = 0.04). In MDS, 35% (15/43) of patients displayed aberrant hypermethylation, a result that trended toward decreased survival but was not quite significant (HR 2.15, *p* = 0.072; Benetatos et al., [@B6]). An independent assessment of 40 AML samples by a second group confirmed aberrant methylation in the MEG3-associated DMRs in AML samples, but not in normal controls (Khoury et al., [@B41]). Importantly, neither study showed MEG3 hypermethylation to be associated with karyotype or disease subtype (Benetatos et al., [@B6]). Although additional studies will be needed to determine the functional role of MEG3 in leukemia, the importance of its interactions with MDM2, p53, and GDF15, as well as p16 in pituitary carcinomas, will likely demonstrate a role for MEG3 in leukemia (Zhang et al., [@B74]).

ncRNA--ncRNA Regulation: Transcribed Ultraconserved Regions and Host Genes
==========================================================================

Within the human genome, 481 transcribed genomic segments have been identified that are 100% conserved between orthologous regions in the human, mouse, and rat (Bejerano et al., [@B5]; Calin et al., [@B13]). Of these "transcribed ultraconserved regions" (T-UCRs), 39% are contained within intergenic sequences and 43% are intronic; the remainder are exonic or exon-overlapping (Mestdagh et al., [@B54]). Like miRNAs, T-UCR locations are closely associated with genomic fragile sites and ubiquitously expressed T-UCRs are frequently associated with cancer-associated genomic regions (CAGRs; Calin et al., [@B14], [@B13]). Microarray analysis has shown that T-UCRs differentially expressed in human malignancies are highly likely to be associated with CAGRs of that tumor type (Calin et al., [@B13]).

Transcribed ultraconserved regions expression has been used to predict disease outcome in both CLL and neuroblastoma samples (Calin et al., [@B13]). In a survey of 133 cancers and 22 normal tissues, a profile of 19 T-UCRs (8 up- and 11 down-regulated) could differentiate between normal, CLL, colorectal, and hepatocarcinoma samples (Calin et al., [@B13]). This study also showed that the expression of five T-UCRs (three intronic and two intergenic) could divide a CLL cohort into two prognostic groups, previously defined by low (favorable) vs. high (poor) ZAP-70 expression (Calin et al., [@B13]). Expression of these diagnostic T-UCRs negatively correlated with the previously defined CLL miRNA signature, suggesting a mechanism for miRNA regulation of these T-UCRs (Calin et al., [@B12]). Of the diagnostic T-UCR profile, three (uc.160, uc.346A, and uc.348) contain miRNAs recognition sites, including targeting by miR-155:: miR-24:: and miR-29 (Calin et al., [@B12]). Repressive activity of miR-155 was confirmed in an *in vitro* assay, while the negative correlations were observed between miR-155?uc.346A and miR-24?uc pairings; 160 were validated in the aforementioned diagnostic cohort (Calin et al., [@B13]). miR-155 over-expression was identified in CLL, while in AML its up-regulation was associated with expanded bone marrow granulocyte and monocyte proliferation (reviewed in Faraoni et al., [@B22]) and miR-24 loss-of-function has been linked to methotrexate resistance in HCT-116 cells (Mishra et al., [@B57]). Interestingly, miR-29a has also been shown to regulate MEG3 expression in hepatocarcinoma cell lines (Braconi et al., [@B8]). Although it is currently unknown whether miRNAs repress T-UCRs, or whether the altered expression of the T-UCRs affects the primary target of the leukemia-associated miRNAs, it is clear that careful regulation of these two ncRNA species is critical to understanding the disease state and for developing ncRNA-associated classification or ncRNA-directed targeted therapy. In addition to miRNA regulation, differential methylation of T-UCR-associated CpG islands (CGI) may also control expression. In a study of 15 leukemia cell lines and 64 primary leukemia samples, differential methylation was seen at three of these CGI (∼60% in cell lines and approximately 18% in primary samples), although the relevance of CGI-mediated hypermethylation to leukemia etiology remains unclear (Lujambio et al., [@B51]). A much larger cohort will need to be investigated before diagnostic implications can be verified.

Long non-coding RNAs targeting by miRNAs is only one example of ncRNA-ncRNA regulation. Deleted in leukemia 2 (Dleu2) is an lncRNA transcribed from 13q14 (Liu et al., [@B50]; Migliazza et al., [@B56]). The Myc-repressed Dleu2 transcript is a host gene for the miR-15a/miR-16-1 cluster, providing the primary transcript from which miR-15a and miR-16-1 are processed (Figure [1](#F1){ref-type="fig"}; Klein et al., [@B44]). While de-regulation of these two miRNAs has long been associated with CLL, deletion-mapping studies have demonstrated that the Dleu2 transcript is frequently disrupted in CLL cell line, and increased expression of this gene leads to reduced proliferation and clonogenicity (Lerner et al., [@B47]). Although further analysis is needed in order to validate these observations, Dleu2 serves as an important example of the intricate co-regulation of lncRNA and miRNAs.

Hematopoietic Regulator lncRNAs as Potential Oncogenic Genes
============================================================

Newly discovered lncRNAs are being characterized at a rapid pace. In hematopoiesis, the antisense lincRNA, HOTAIRM1, has recently been identified as an essential regulator of myeloid cell differentiation. This lincRNA is transcribed from within the HOXA cluster and regulates HOXA1, HOXA4, CD11b, and CD18 during retinoic acid-induced differentiation of an acute promyelocytic leukemia cell line (Zhang et al., [@B72]). EGO is expressed during eosinophil development and is essential for major basic protein and eosinophil-derived neurotoxin mRNA expression (Wagner et al., [@B67]). Ørom et al. ([@B59]) identified several lncRNA activators, one of which strongly induced expression of SCL/TAL1. Although these lncRNAs have not yet been associated with hematopoietic malignancies, such critical regulators of cell fate are likely to be identified as potent regulators of tumorigenicity.

Conclusion
==========

It has become evident in recent years that the de-regulation of miRNAs and lncRNAs plays a critical role in malignant transformation, tumor cell behavior and, in particular, hematologic malignancies. These ncRNAs could prove to be increasingly useful in the development of much needed novel diagnostic, prognostic, and therapeutic strategies for acute and chronic leukemias.
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